Ireland will be undergoing many changes come 1st August 2016 to their market access process.
There are some key changes to the pricing features such new measures for biologics and biosimilars, changes to the rebate percentages and more.
One of the biggest changes is that Ireland will be increasing its basket reference, from which they base current medicinal product prices off of, from 9 countries to 14 (which with Ireland constituted the EU-15 pre-2004 accession)
The 14 countries will include the existing 9 and 5 new countries:
- Austria, Belgium, Denmark, Finland, France, Germany, Greece, Italy, Luxembourg, Netherlands, Portugal, Spain, Sweden and UK
The UK will be reconsidered following outcome of Brexit as to whether it will remain in the reference basket.